Orchard Therapeutics PLC (ORTX)
Company Description
Orchard Therapeutics plc, a biopharmaceutical company, develops gene therapies for serious and life-threatening rare diseases in the United Kingdom, European Union, and the United States.
The company's gene therapy approach seeks to transform a patient's hematopoietic stem cells into a gene-modified cellular drug product to treat the patient's disease through a single administration.
It provides Strimvelis, a gammaretroviral-based product for the treatment of adenosine deaminase-severe combined immunodeficiency (ADA-SCID). The company's clinical development products comprise OTL-101 for the treatment of ADA-SCID; OTL-200 to treat metachromatic leukodystrophy; OTL-103 for the treatment of Wiskott-Aldrich syndrome; OTL-102 for X-linked chronic granulomatous disease; and OTL-300 for transfusion-dependent beta-thalassemia.
Its preclinical programs include OTL-203 for mucopolysaccharidosis type I, OTL-201 for mucopolysaccharidosis type MPS-IIIA, and OTL-202 for mucopolysaccharidosis type IIIB.
It has a strategic collaboration agreement with Pharming Group N.V. for research, development, manufacturing, and commercialization of OTL-105, an investigational ex vivo autologous hematopoietic stem cell gene therapy for the treatment of hereditary angioedema.
The company was formerly known as Orchard Rx Limited. Orchard Therapeutics plc was founded in 2015 and is headquartered in London, the United Kingdom.
| Country | United Kingdom |
| Founded | 2015 |
| IPO Date | Oct 31, 2018 |
| Industry | Biotechnology |
| Sector | Health Care |
| Employees | 259 |
Contact Details
Address: 108 Cannon Street London EC4N 6EU United Kingdom | |
| Phone | 44 20 3 808 8286 |
| Website | orchard-tx.com |
Stock Details
| Ticker Symbol | ORTX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | US Dollars |
| CIK Code | 0001748907 |
Key Executives
| Name | Position |
|---|---|
| Dr. Bobby Gaspar M.D., Ph.D. | Chief Executive Officer, Member of Scientific Advisory Board and Executive Director |
| Frank E. Thomas | President and Chief Operating Officer |
| Dr. Nicoletta Loggia Ph.D. | Chief Technical Officer |
| Dr. Fulvio Mavilio Ph.D. | Chief Scientific Officer |
| Renee T. Leck | Director of Investor Relations |
| Benjamin Navon | Director of Corporate Communications |
| John Cerio | Chief Human Resource Officer |
| Dr. Anne Dupraz-Poiseau | Chief Development Officer |
| Robin Kenselaar | Senior Vice President and GM of EMEA Commercial Operations |
| Braden Parker | Chief Commercial Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 8, 2022 | 8-K | Current report |
| Apr 5, 2022 | 4 | Statement of changes in beneficial ownership of securities |
| Apr 4, 2022 | 4 | Statement of changes in beneficial ownership of securities |
| Mar 30, 2022 | S-3 | Registration statement under Securities Act of 1933 |
| Mar 30, 2022 | 10-K | Annual report [Section 13 and 15(d), not S-K Item 405] |
| Mar 30, 2022 | POSASR | Post-effective Amendment to an automatic shelf registration statement |
| Mar 30, 2022 | 8-K | Current report |
| Feb 14, 2022 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals |
| Feb 14, 2022 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Feb 11, 2022 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals |
| View All SEC Filings | ||